InsiderTrades.com logo
Anna Nijdam net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anna Nijdam Biography and Net Worth

Insider of Pharvaris

Ms. Nijdam joined the Company in 2020, with over 12 years’ experience in the financial industry as a chartered accountant. From 2008 until 2020, Ms. Nijdam worked in the Assurance Services group at Ernst & Young Accountants LLP in Rotterdam, the Netherlands, where she held various leadership positions, including most recently serving as a Senior Manager. Ms. Nijdam is treasurer at the Entrepreneurs Foundation and previously served as member of the Associations Audit Committee of Hockey Club Rotterdam and as a member of the supervisory board of Access to Seeds foundation. Ms. Nijdam holds a master’s in economics from the Erasmus University of Rotterdam and a Register Accountant title (Dutch Certified Public Accountant) from Nivra Nyenrode in the Netherlands.

What is Anna Nijdam's net worth?

The estimated net worth of Anna Nijdam is at least $1.62 million as of June 4th, 2026. Nijdam owns 46,275 shares of Pharvaris stock worth more than $1,616,849 as of July 18th. This net worth estimate does not reflect any other investments that Nijdam may own. Learn More about Anna Nijdam's net worth.

How do I contact Anna Nijdam?

The corporate mailing address for Nijdam and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Anna Nijdam's contact information.

Has Anna Nijdam been buying or selling shares of Pharvaris?

Anna Nijdam has not been actively trading shares of Pharvaris during the last quarter. Most recently, Anna Nijdam sold 2,670 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $30.87, for a transaction totalling $82,422.90. Following the completion of the sale, the insider now directly owns 46,275 shares of the company's stock, valued at $1,428,509.25. Learn More on Anna Nijdam's trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Elisabeth Bjork (Director), Robert Glassman (Director), Anne Lesage (Chief Early Development Officer), Anne Lesage (Insider), Peng Lu (Chief Medical Officer), Berndt Modig (Chief Executive Officer, Director (CH)), Viviane Monges (Director), David Nassif (CFO), Anna Nijdam (Insider), and Wim Souverijns (Insider). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 33 times. They sold a total of 328,981 shares worth more than $10,458,873.39. The most recent insider tranaction occured on June, 30th when Director Johannes Gerardus Chri Schikan sold 30,712 shares worth more than $1,089,968.88. Insiders at Pharvaris own 11.8% of the company. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 6/30/2026.

Anna Nijdam Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/4/2026Sell2,670$30.87$82,422.9046,275View SEC Filing Icon  
5/22/2026Sell5,501$30.74$169,100.7448,945View SEC Filing Icon  
5/21/2026Sell1,829$30.60$55,967.4048,945View SEC Filing Icon  
See Full Table

Anna Nijdam Buying and Selling Activity at Pharvaris

This chart shows Anna Nijdam's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $34.94
Low: $33.24
High: $35.07

50 Day Range

MA: $32.16
Low: $28.81
High: $35.96

2 Week Range

Now: $34.94
Low: $19.12
High: $36.60

Volume

236,448 shs

Average Volume

548,634 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A